Most recently on April 17, 2020, pemigatinib, an selective inhibitor of FGFR isoforms 1, 2 and 3 got approval for FGFR2+ cholangiocarcinoma later line treatment upon the data from the FIGHT-202 study with an ORR of 36% 13. Here, FGFR2 is linked to cholangiocarcinoma.